Announcements Trials

Browse Landscape

Phase

Status

Withdrawn 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Follicular 2 Triple Negative Breast Neoplasms 1 Recurrence 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell, Marginal Zone 1 Breast Neoplasms 1

Interventions

Paclitaxel 28 Trastuzumab 22 Cyclophosphamide 21 Doxorubicin 14 Docetaxel 14 Carboplatin 11 exemestane 10 Radiotherapy 10 Letrozole 10 Capecitabine 10 pembrolizumab 8 Lapatinib 8 Fulvestrant 8 Neoadjuvant Therapy 6 Goserelin 6 Bevacizumab 6 Anastrozole 6 pertuzumab 5 palbociclib 5 eribulin 5 abemaciclib 5 Therapeutics 5 Magnetic Resonance Spectroscopy 5 Epirubicin 5 Chemotherapy, Adjuvant 5 Aromatase Inhibitors 5 tucatinib 4 Vinorelbine 4 Taxes 4 Tamoxifen 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Breast Neoplasms × parsaclisib × Clear all

NCT04142554 2020-11-03

LCCC1820

UNC Lineberger Comprehensive Cancer Center

Phase 1 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡